Clinical and genetic features of idiopathic membranous nephropathy in russian patients


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective. Evaluation of the clinical features of idiopathic membranous nephropathy (1MN) in Russian patients depending on seropositivity for antibodies to the m-type phospholipase a2 receptor (anti-pla2R), as well as the association between anti-pla2R and polymorphic markers RS4664308 of the pla2R1 gene and rs2187668 of the hla-dqa/gene. material and methods. clinical and laboratory parameters of 34 patients with imn at the time of nephrobiopsy, the severity of morphological changes and the response to immunosuppressive therapy depending on the presence of anti-pla2R were analyzed; genotyping of polymorphic markers rs4664308 of the pla2R/ gene and rs2/87668 of the hla-dqa/gene compared with 100 healthy control subjects was performed. results. ANT1-PLA2R POSITIVITY was associated with a later manifestation of the disease (ANT1-PLA2R “+”: 53 [27-77] years; ANT1-PLA2R “-” 40 [22-54] YEARS; P=0.013); duration OF IMN before nephrobiopsy WAS COMPARABLE IN BOTH GROUPS. THERE WERE NO statistically significant differences in seropositive and seronegative groups in terms of blood pressure, kidney function, and frequency of nephrotic syndrome (NS); in patients with anti-pla2R positivity, however, there was a tendency to more frequent detection of proteinuria (PU) >4 g/day (76 AND 37.5%, RESPECTIVELY; p=0.080). an association of the studied polymorphic markers with AN INCREASED risk OF DEVELOPING imn WAS FOUND: FOR THE A/a GENOTYPE OF THE RS4664308 polymorphic marker OF THE PLA2R/gene, THE ODDS ratio [or] WAS 3.88 (95% CONFIDENCE interval [Cl] - 1.69-8.94; P<0.001 ), AND FOR THE a/a genotype OF THE RS2/87668 POLYMORPHIC marker OF THE HLA gene, THE or REACHED 8.75 (95% Cl - 1.61-47.55; P=0.010). ANTI-PLA2R “ + ” patients showed a TENDENCY TOWARDS MORE FREQUENT CARRIAGE OF THE A/A GENOTYPE OF THE POLYMORPHIC MARKER RS4664308 OF THE PLA2R/ GENE ASSOCIATED WITH AN INCREASED RISK OF DEVELOPMENT OF IMN (P=0.052). Conclusion. The relationship between the presence of anti-PLA2R and the clinical and laboratory features of IMN was shown. variants of the pla2R/ and hla-dqa/ genes associated with an increased risk of development of imn were identified, with A TENDENCY TO A HIGHER FREQUENCY OF THE PLA2R1 GENE A/A GENOTYPE IN ANTI-PLA2R-POSITIVE PATIENTS.

Texto integral

Acesso é fechado

Sobre autores

Irina Bobyleva

Sechenov First Moscow State Medical University

Email: irinamd@inbox.ru
Postgraduate Student at the Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine Moscow, Russia

Patimat Kakhsurueva

Sechenov First Moscow State Medical University

Email: kpa0807@mail.ru
Postgraduate Student at the Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine Moscow, Russia

Elena Kamyshova

Sechenov First Moscow State Medical University

Email: kamyshova-es@yandex.ru
Associate Professor at the Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine Moscow, Russia

Irina Bobkova

Sechenov First Moscow State Medical University

Email: irbo.mma@maill.ru
Doctor of Medical Sciences, Professor at the Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine Moscow, Russia

Olga Li

Sechenov First Moscow State Medical University

Email: shoa1978@bk.ru
Teaching Assistant at the Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine Moscow, Russia

Agunda Kuchieva

Sechenov First Moscow State Medical University

Email: agunda_81@mail.ru
Nephrologist at the Artificial Kidney Department, Clinic for Rheumatology, Internal and Occupational Diseases named after E.M. Tareev Moscow, Russia

Ekaterina Filatova

Sechenov First Moscow State Medical University

Email: filatevich@gmail.com
Resident Physician at the Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine Moscow, Russia

Elena Zakharova

S.P. Botkin City Clinical Hospital of the Moscow Healthcare Department

Email: helena.zakharova@gmail.com
Head of the Department of Nephrology №. 24 Moscow, Russia

Aleksey Borisov

Burdenko Main Military Clinical Hospital

Email: bag22@rambler.ru
Head of the Department of Nephrology Moscow, Russia

Bibliografia

  1. Beck L.H. Jr, Bonegio R.G., Lambeau G., Beck D.M., Powell D.W., Cummins T.D., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 2009;361(1):11-21. doi: 10.1056/NEJMoa0810457.
  2. Debiec H., Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N. Engl. J. Med. 2011;364(7):689-690. doi: 10.1056/NEJMc1011678.
  3. Ronco P., Debiec H. Updates in renal medicine 1. Pathophysiological advances in membranous nephropathy: time for a shift in patient’s care. Lancet. 2015;385(9981):1983-1992. doi: 10.1016/S0140-6736(15)60731-0.
  4. Sinico R.A., Mezzina N., Trezzi B, Ghiggeri G.M., Radice A. Immunology of membranous nephropathy: From animal models to humans. Clin. Exp. Immunol. 2016;183(2):157-165. doi: 10.1111/cei.12729.
  5. Francis J.M., Beck L.H Jr., Salant D.J. Membranous nephropathy: A journey frombench to bedside. Am. J. Kidney Dis. 2016;68(1):138-147. Doi:10.1053/j. ajkd.2016.01.030.
  6. Akiyama S., Imai E., Maruyama S. Immunology of membranous nephropathy [version 1; peer review: 3 approvedj F1000. Research. 2019, 8(F1000 Faculty Rev):734. https://doi.org/10.12688/f1000research.17589.1.
  7. Hu S.L., Wang D., Gou W.J., Lei Q.F., et al. Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis. J. Nephrol. 2014;27:111-116. doi: 10.1007/s40620-014-0042-7.
  8. Dai H., Zhang H., He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci. Rep. 2015;5:8803. doi: 10.1038/srep08803.
  9. Hofstra J.M., Beck L.H. Jr, Beck D.M., et al: Antiphospholipase A 2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2011;6:1286-1291. doi: 10.2215/CJN.07210810.
  10. Kanigicherla D., Gummadova J., McKenzie E.A., et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013;83:940-948. doi: 10.1038/ki.2012.486.
  11. Hoxha E., Thiele I., Zahner G., et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J. Am. Soc. Nephrol. 2014;25:1357-1366. doi: 10.1681/ASN.2013040430.
  12. Ruggenenti P., Debiec H., Ruggiero B., et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J. Am. Soc. Nephrol. 2015;26:2545-2558. doi: 10.1681/ASN.2014070640.
  13. Li X., Wei D., Zhou Z., et al. Anti-PLA2R antibodies in Chinese patients with membranous nephropathy. Med. Sci. Monit. 2016;22:1630-1636. doi: 10.12659/MSM.896090.
  14. Pang L., Zhang A.M., Li H.X., Du J.L., et al. Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: a cross-sectional study. Medicine (Baltimore). 2017;96:e7218. doi: 10.1097/MD.0000000000007218.
  15. Kim Y.G., Choi Y.W., Kim S.Y., et al. Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy. Am. J. Nephrol. 2015;42:250-257. doi: 10.1159/000440983.
  16. Timmermans S.A., Abdul Hamid M.A., Cohen Tervaert J.W, Damoiseaux J.G., van Paassen P; Limburg Renal Registry. Anti-PLA2R antibodies as a prognostic factor in PLA2Rrelated membranous nephropathy. Am. J. Nephrol. 2015;42:70-77. doi: 10.1159/000437236.
  17. Jullien P., Seitz Polski B., Maillard N., et al. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy. Clin. Kidney J. 2017;10:209-214. Doi: 10.1093/ ckj/sfw121.
  18. Liu Y.H., Chen C.H., Chen S.Y., Lin Y.J., Liao W.L., Tsai C.H., et al. Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan. J. Biomed. Sci. 2010;17:81. doi: 10.1186/1423-0127-17-81.
  19. Kim S., Chin H.J., Na K.Y., Kim S., Oh J., Chung W., et al. Progressive Renal Disease and Medical Informatics and Genomics Research (PREMIER) members: Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy. Nephron. Clin. Pract. 2011;117(3):253-258. doi: 10.1159/000320194.
  20. Stanescu H.C., Arcos-Burgos M., Medlar A., Bockenhauer D., Kottgen A., Dragomirescu L., Voinescu C., et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N. Engl. J. Med. 2011;364(7):616-626. doi: 10.1056/NEJMoa1009742.
  21. Lv J., Hou W., Zhou X., Liu G., Zhou F., Zhao N., et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J. Am. Soc. Nephrol. 2013;24(8):1323-1329. doi: 10.1681/ASN.2012080771.
  22. Bullich G., Ballann J., Oliver A., Ayasreh N., Silva I., Santin S., et al. HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2014;9(2):335-343. Doi: 10.2215/ CJN.05310513.
  23. Saeed M., Beggs M.L., Walker P.D., Larsen C.P. PLA2R-associated membranous glomerulopathy is modulated by common variants in PLA2R1 and HLA-DQA1 genes. Genes. Immun. 2014;15(8):556-561. Doi: 10.1038/ gene.2014.50.
  24. Ramachandran R., Kumar V., Kumar A., Yadav A.K., Nada R., Kumar H., et al. PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians. Nephrol. Dial. Transplant. 2016;31(9):1486-1493. doi: 10.1093/ndt/gfv399.
  25. Coenen M.J., Hofstra J.M., Debiec H., Stanescu H.C., Medlar A.J., Stengel B, et al. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 2013;24(4):677-683. doi: 10.1681/ASN.2012070730.
  26. Cui Z, Xie L.J., Chen F.J., Pei Z.Y., Zhang L.J., Qu Z., et al. MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 2017;28(5):1651-1664. doi: 10.1681/ASN.2016020114.
  27. Sekula P., Li Y., Stanescu H.C., Wuttke M., Ekici A.B., Bockenhauer D., et al.; GCKD Investigators. Genetic risk variants for membranous nephropathy: Extension of and association with other chronic kidney disease aetiologies. Nephrol. Dial. Transplant. 2017;32(2):325-332. doi: 10.1093/ndt/gfw001.
  28. Kaga H., Komatsuda A., Omokawa A., Okuyama S., Mori K., Wakui H., Takahashi N. Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy. Clin. Exp. Nephrol. 2018;22(2):275-282. doi: 10.1007/s10157-017-1471-0.
  29. Добронравов В.А., Майер Д.А., Бережная О.В. и др. Мембранозная нефропатия в российской популяции. Тер. архив. 2017;6:21-29.
  30. Добронравов В.А., Лапин С.В., Лазарева Н.М., Сиповский В.Г., Трофименко И.И. и др. Циркулирующие антитела к рецептору фосфолипазы А2 при первичной мембранозной нефропатии. Нефрология. 2012;16(4):39-44.
  31. Song E.J., Jeong K.H., Yang Y.A., Lim J-H., Jung H-Y., et al. Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy. Kidney Res. Clin. Pract. 2018;37:248-256. doi: 10.23876/j.krcp.2018.37.3.248.
  32. Couser W.G. Primary Membranous Nephropathy. Clin J. Am. Soc. Nephrol. 2017;12:983-997. Doi: https://doi.org/10.2215/CJN.11761116.
  33. Le W.B., Shi J.S., Zhang T., Liu L., Qin H.Z., Liang S., et al. HLA-DRB1* 15:01 and HLADRB3*02:02 in PLA2R-related membranous nephropathy. J. Am. Soc. Nephrol. 2017;28(5):1642-1650. Doi: 10.1681/ ASN.2016060644

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies